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Introduction. Suspected locally advanced prostate carcinoma shows lymph node involvement in a high percentage of cases. For a
long time, such patients were not radically prostatectomised. In recent years, however, this viewpoint has changed. Material and
Methods. We analysed a single-centre series of 34 patients with suspected locally advanced prostate cancer to establish predictive
parameters for lymph node metastasis. All patients underwent radical prostatectomy between 2007 and 2010. Results. Of the
34 patients, 26% showed pathological stage T3a, 59% pT3b, and 15% pT4. Median preoperative PSA level was 25 ng/mL, and
five patients had had neoadjuvant antihormonal treatment. Positive margins were found in 76% of patients. Patients without
neoadjuvant treatment showed it in 79%, and after preoperative antihormonal treatment the rate was 60%. Positive margins were
associated with lymph node involvement in 85% of cases, complete resection was associated only in 50% of cases. Conclusions.
Positive surgical margins play an important predictive role when estimating lymph node involvement in patients with locally
advanced prostate carcinoma. Neoadjuvant antihormonal therapy is associated with a relevant reduction in the rate of positive
margins but not with the rate of lymph node metastasis. As such, a combination of antihormonal and surgical treatment should
be considered.
1. Introduction
According to the European Association of Urology (EAU)
guidelines on prostate carcinoma, radical prostatectomy
(RP) is the standard treatment for stage T2N0M0 prostate
cancer, equivalent to radiation therapy. For locally advanced
prostate cancer, recommendations are less concise. In
selected patients RP in combination with extended pelvic
lymphadenectomy may be feasible. A study by Gontero et al.
showed no relevant differences in the rate of comorbidities,
only transfusion and lymphocele rate appeared more often
compared to T2N0M0 prostate carcinoma. Cancer-specific
survival (CSS) was 90% for T3-4, N0, M0 prostate cancer,
and 99% for organ-confined cancer [1].
In lymph node positive prostate cancer after RP and
adjuvant hormonal treatment 10-year CSS reaches 80% [2].
However, known lymph node metastasis remains a con-
traindication for most urologists for radical prostatectomy,
and antihormonal treatment is initiated. Since then, the
standing of radical prostatectomy as a treatment in this
indication has been promoted by the findings of Engel et al.,
even in cases of suspected or proven lymph node metastasis.
They were able to show that the survival of patients with
lymph node metastasis was improved by radical prostatec-
tomy when compared to patients who broke off surgery [3].
Adjuvant radiotherapy combined with hormonal treatment
in lymph node involvement is advantageous when compared
with hormonal treatment alone [4]. Preoperative prediction
of lymph node involvement is challenging, especially in
current-era prostate cancer with high percentage of low-risk
prostate carcinoma that do not fit with the Roach formula,
which overpredicts lymph node metastasis [5, 6].
We analysed a single-centre collective of patients sus-
pected for ≥cT3 prostate carcinoma after radical prostate-
ctomy and pelvic lymphadenectomy in order to establish
the predictability of lymph node involvement by virtue of
histopathological parameters.
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2. Material and Methods
We retrospectively collected clinical and histopathological
data of 34 patients who underwent RP for suspected ≥cT3
prostate cancer. Open surgery took place between 2007 and
2010 in a German single centre.
Suspect digital rectal examination (DRE), elevated PSA
level, lower urinary tract symptoms (LUTS) or hydronephro-
sis led to the suspicion of prostate cancer, respectively. Diag-
nosis was assessed by ultrasound-guided prostate biopsy.
Locally advanced stage was indicated by suspect digital rectal
examination and confirmed by computed tomography (CT).
There was no evidence of lymph node involvement or organ
metastasis in CT assessment. Before surgical therapy all
patients underwent bone scans without detection of skeletal
metastasis. To reduce local tumour mass, five patients were
neoadjuvantly treated antihormonally.
We assessed pT and pN stage, the share of positive
margins (R1) and compared bioptic and specimen Gleason
scores as well as the predictive value of these parameters with
regard to the existence of lymph node metastasis.
3. Results and Discussion
3.1. Clinical and Histopathological Patient Data. 34 patients
with a median age of 65 years (range 55–75 years) and
with suspected locally advanced prostate carcinoma had
a median PSA level of 23 ng/mL (range 5–141 ng/mL) at
the time of diagnosis. The day prior to surgery median
PSA level was 25 ng/mL, but some patients only had one
PSA testing run before surgery. Four out of five patients
who underwent neoadjuvant antihormonal therapy had no
further preoperative PSA testing; one patient’s PSA level
decreased from 98 to 2 ng/mL.
Themedian Gleason score from the prostate biopsy was 8
(range 6–10) and from the prostatectomy specimen 9 [7–9].
Only in 44% Gleason score of prostate biopsy and specimen
was identical; underestimation in prostate biopsy score of
one to three points was detected in 41% of patients and
overestimation of one score point in 15%. Patients showed
pathological stage pT3a in 26%, pT3b in 59% and pT4
in 15%. For details see Table 1. Residual tumour defined
by cancer positive margin of the prostatectomy specimen
was found in 76%. Neoadjuvant treatment seemed to have
a protective effect, with positive margins in 60% of these
patients whilst patients without preoperative antihormonal
therapy showed residual tumour in 79% of cases. Whilst 85%
of patients with positive margins had lymph node metastasis,
only 50% of the patients without residual prostate tumour
mass showed lymph node involvement (Table 2). Median
number of dissected lymph nodes was 15 (range 6–32), in
the case of lymph node metastasis, and the median number
of metastasis was 2 (range 1–10).
3.2. Discussion of Predictive Factors for the Existence of Lymph
Node Metastasis. In a multicentre series of 712 patients,
Spahn et al. showed that PSA levels >20 ng/mL were asso-
ciated with organ-confined tumour in 33%, with Gleason
score ≤6 in prostate biopsy in 8%, with negative surgical
Table 1: Characteristics of patients with locally advanced prostate
carcinoma.
No. Age PSA GS biopsy GS specimen pT stage pN stage
1 60 77,3 6 7 pT3b pN1
2 66 36,0 6 7 pT3a pN1
3 68 30,2 6 7 pT3a pN1
4 62 58,0 6 8 pT3b pN0
5 64 35,6 6 9 pT3a pN0
6 59 60,0 6 9 pT3b pN1
7 60 31,5 7 7 pT3b pN1
8 65 52,0 7 7 pT3b pN1
9 70 56,0 7 7 pT3b pN1
10 74 17,8 7 8 pT3b pN0
11 63 21,4 7 8 pT3b pN1
12 75 14,2 7 9 pT3b pN1
13 55 5,8 7 9 pT4 pN0
14 61 100,0 7 9 pT3a pN0
15 63 14,1 7 9 pT4 pN1
16 62 47,0 8 7 pT3b pN1
17 74 23,3 8 7 pT3a pN1
18 63 73,0 8 8 pT3b pN1
19 68 11,5 8 8 pT3a pN0
20 71 15,2 8 8 pT3a pN0
21 70 9,5 8 8 pT3b pN1
22 71 141,0 8 9 pT3b pN1
23 65 138,0 8 9 pT4 pN1
24 64 34,7 9 8 pT4 pN1
25 70 7,2 9 9 pT3a pN1
26 69 14,6 9 9 pT3b pN1
27 60 13,0 9 9 pT3b pN1
28 70 100,0 9 9 pT3b pN1
29 58 25,0 9 9 pT3a pN0
30 67 100,0 9 9 pT3b pN1
31 61 22,0 9 9 pT3b pN1
32 68 2,2 9 9 pT3b pN1
33 56 15,1 10 9 pT3b pN1
34 70 15,0 10 9 pT4 pN1
GS: Gleason score.
margins in 54%, and with no lymph node involvement
in 85% of cases, respectively [7]. Patients with PSA levels
>20 ng/mL and suspected locally advanced prostate cancer
had positive margins in 79% and lymph node invasion
in 51% of cases. Our results confirmed these findings by
showing residual tumour and lymph node metastasis in 76%
of cases. Using the same series, Gontero et al. found that the
PSA level was of prognostic relevance with 26% cured by
surgery alone when PSA was 20–50 ng/mL but only about 7–
9%with PSA >50 ng/mL [8]. A single-centre analysis of more
than 2 600 patients with locally advanced prostate cancer
after RP and adjuvant androgen deprivation revealed the
Gleason score to be the most important prognostic factor
[9]. In our much smaller series we did not attempt to show
cancer-specific survival, but for the prediction of T stage and
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Table 2: Association of positive margins with lymph node metasta-
sis.
No. Age Neoadj. HT R stage pN stage
1 60 No R1 pN1
2 66 No R1 pN1
3 68 No R1 pN1
4 62 No R1 pN0
5 64 No R0 pN0
6 59 No R1 pN1
7 60 Yes R0 pN1
8 65 No R1 pN1
9 70 No R1 pN1
10 74 No R0 pN0
11 63 No R1 pN1
12 75 No R1 pN1
13 55 No R1 pN0
14 61 Yes R1 pN0
15 63 No R1 pN1
16 62 Yes R0 pN1
17 74 No R0 pN1
18 63 No R1 pN1
19 68 No R0 pN0
20 71 No R0 pN0
21 70 No R1 pN1
22 71 No R1 pN1
23 65 No R1 pN1
24 64 No R1 pN1
25 70 No R0 pN1
26 69 No R1 pN1
27 60 No R1 pN1
28 70 Yes R1 pN1
29 58 No R1 pN0
30 67 No R1 pN1
31 61 No R1 pN1
32 68 Yes R1 pN1
33 56 No R1 pN1
34 70 No R1 pN1
HT: antihormonal treatment.
lymph node involvement, the Gleason score was not themost
obvious parameter. Evidence of residual tumour presence on
the surgical margins in our patient collective was the most
important predictive parameter for lymph node metastasis.
76% positive margins corresponded with 76% stage pN1.
Patients with positive margins had synchronous lymph node
metastasis in 85%, and negativemargins were only associated
in 50% with lymph node metastasization. Another study on
a collective of high-risk prostate cancer (stage ≥pT3 in 89%)
showed positive margins in 83% but only in 28% pN1 disease
[10]. Oh et al. showed that positive margins in stage pT2
prostate cancer lead to a worse outcome, similar to that of
patients with locally advanced prostate carcinoma [11].
4. Conclusions
Alongside the Gleason score and pathological T stage,
the presence of positive surgical margins is an important
predictive factor in estimating lymph node involvement.
Neoadjuvant antihormonal therapy does lead to a relevant
reduction in the rate of positive margins, but not to a
reduction in the rate of lymph node metastasis. As such,
antihormonal and surgical treatment should be considered
in combination for the therapy of locally advanced prostate
cancer.
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